What’s New in Antiretroviral Safety and Tolerability: Implications for Treatment

In this interactive video module, expert faculty discuss safety and tolerability considerations for ART regimen selection and strategies to individualize regimen selection to reduce AEs associated with ART in persons with HIV

Kristine Erlandson, MD Rajesh T. Gandhi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: April 24, 2020 Expired: April 23, 2021

Module Overview (2 minutes)

Introduction to Individualized ART Management (25 minutes)

ART and Weight Gain (15 minutes)

ART Safety in Women of Childbearing Potential (13 minutes)

Considerations for ART Optimization in Patients With Multimorbidity/Polypharmacy (23 minutes)

Review data and guideline recommendations informing ART management for specific patient populations to improve tolerability and minimize adverse events and potential drug-drug interactions

Kristine Erlandson, MD Rajesh T. Gandhi, MD Released: April 24, 2020

During the past 2 years, guidelines have shifted their recommendations on use of DTG around the time of conception and during pregnancy. As data and guidance evolve, which ART regimens should we recommend to PWH in these settings?

Brian Wood, MD Released: April 20, 2020

Certain INSTIs and TAF are associated with excessive weight gain in PWH. Here’s my take on what we know, what we don’t, and the need for clinical trials to assess mechanism and management strategies.

Jordan E. Lake, MD, MSc Released: April 27, 2020